Efavirenz, emtricitabine, tenofovir disoproxil

Sold as Atripla, Odimune, Trenvir, Tribuss, Atroiza, Heftenam, Comtrefev, Eftenem, Triploco, Rizene, Trivenz, Atenef, Citenvir, Truno, Triolar, Virtem, Virastiva, Trionce, Trivage, Triemta, Tripavir, Hetripco, Tabex, Teevir

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

Loading Wikipedia summary

Registration

Applicants: 14
Registrations: 24
Schedule source: Consolidated Schedules 06 July 2026

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Msd (Pty) LtdCancelled	Atripla	Not stated	420729	S4	None
Cipla Medpro Manufacturing (Pty) LtdCertificate held by Cipla Medpro Manufacturing (Pty) Ltd.	Odimune, Trenvir	200 mg, 300 mg, 600 mg	440779, 440780	S4	PI PIL
Pharmacare limited û woodmeadCertificate held by Pharmacare limited	Tribuss	200 mg, 300mg, 600mg	440980	S4	PI PIL
Viatris Healthcare (Pty) Ltd	Atroiza	Not stated	450172	S4	None
Hetero Drugs South Africa (Pty) Ltd	Heftenam, Comtrefev, Hetripco, Tabex	Not stated	460757, 470035, 510200, 510201	S4	None
Specpharm (Pty) LtdCancelled	Eftenem	Not stated	470118	S4	None
Adcock ingram limited	Triploco, Rizene, Trivenz	600 mg, 200 mg, 300 mg	470326, 470327, 470328	S4	PI PIL
Sonke Pharmaceuticals (Pty) Ltd	Atenef	600 mg, 200 mg, 300 mg	470483	S4	PI PIL
Novagen Pharma (Pty) LtdCancelled	Citenvir	Not stated	470504	S4	None
Aurobindo Pharma (Pty) Ltd	Truno	600/200/300	470572	S4	None
Macleods Pharmaceuticals SA (Pty) Ltd	Triolar, Trivage, Triemta, Tripavir	tablets	471006, 510120, 510121.12, 510122.12	S4	None
Emcure- Pharmaceutical South Africa (Pty) Ltd	Virtem	Not stated	490105	S4	None
Innovata pharmaceuticalsCertificate held by Innovata Pharmaceuticals (Pty) Ltd1 of 2 cancelled	Virastiva, Teevir	300 mg, 600 mg, 200 mg	490676, 510579	S4	PI PIL
Barrs Pharmaceutical Industries (Pty) Ltd	Trionce	Not stated	500180	S4	None

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Atripla EACH TABLET CONTAINS EFAVIRENZ 600,0 mgEMTRICITABINE 200,0 mgTENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Not listed	42072942/20.2.8/0729	Cancelled	S4	None
Odimune EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	200 mg, 300 mg, 600 mgFilm-coated tablets.	44077944/20.2.8/0779Approved 23 October 2025	Registered	S4	PI PIL
Trenvir EACH TABLET CONTAINS EFAVIRENZ 600,0 mgEMTRICITABINE 200,0 mgTENOFOVIR DISOPROXIL FUMARATE 300,0 mg	200 mg, 300 mg, 600 mgFilm-coated tablets.	44078044/20.2.8/0780Approved 23 October 2025	Registered	S4	PI PIL
Tribuss EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	200 mg, 300mg, 600mgFilm-coated tablet	44098044/20.2.8/0980Approved 25 November 2022	Registered	S4	PI PIL
Atroiza EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Not listed	45017245/20.2.8/0172	Registered	S4	None
Heftenam EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Not listed	46075746/20.2.8/0757	Registered	S4	None
Comtrefev EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Not listed	47003547/20.2.8/0035	Registered	S4	None
Eftenem EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Not listed	47011847/20.2.8/0118	Cancelled	S4	None
Triploco EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	600 mg, 200 mg, 300 mgFilm-coated tablet.	47032647/20.2.8/0326Approved 6 March 2025	Registered	S4	PI PIL
Rizene EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	600 mg, 200 mg, 300 mgFilm-coated tablets	47032747/20.2.8/0327Approved 6 March 2025	Registered	S4	PI PIL
Trivenz EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	600 mg, 200 mg, 300 mgFilm-coated tablets	47032847/20.2.8/0328Approved 6 March 2025	Registered	S4	PI PIL
Atenef EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	600 mg, 200 mg, 300 mgFilm-coated tablets	47048347/20.2.8/0483Approved 20 July 2018	Registered	S4	PI PIL
Citenvir EACH TABLET CONTAINS: EFAVIRENZ 600,0 mg, EMTRICITABINE 200,0 mg , TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Not listed	47050447/20.2.8/0504	Cancelled	S4	None
Truno 600/200/300 EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	600/200/300	47057247/20.2.8/0572	Registered	S4	None
Triolar EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Not listed	47100647/20.2.8/1006	Registered	S4	None
Virtem EACH TABLET CONTAINS :EFAVIRENZ 600,0 mg, EMTRICITABINE 200,0 mg, TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Not listed	49010549/20.2.8/0105	Registered	S4	None
Virastiva EACH TABLET CONTAINS : EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Not listed	49067649/20.2.8/0676	Cancelled	S4	None
Trionce EACH TABLET CONTAINS : EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Not listed	50018050/20.2.8/0180	Registered	S4	None
Trivage tablets EACH TABLET CONTAINS :EFAVIRENZ 600,0 mg, EMTRICITABINE 200,0 mg, TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Tablets	51012051/20.2.8/0120	Registered	S4	None
Triemta tablets EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Tablets	510121.1251/20.2.8/0121.120	Registered	S4	None
Tripavir tablets EACH TABLET CONTAINS EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Tablets	510122.1251/20.2.8/0122.120	Registered	S4	None
Hetripco EACH TABLET CONTAINS EFAVIRENZ 600,0 mg; EMTRICITABINE 200,0 mg; TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Not listed	51020051/20.2.8/0200	Registered	S4	None
Tabex EACH TABLET CONTAINS EFAVIRENZ 600,0 mg; EMTRICITABINE 200,0 mg; TENOFOVIR DISOPROXIL FUMARATE 300,0 mg	Not listed	51020151/20.2.8/0201	Registered	S4	None
Teevir EACH TABLET CONTAINS: TENOFOVIR DISOPROXIL FUMARATE 300,0 mg EFAVIRENZ 600,0 mg EMTRICITABINE 200,0 mg	300 mg, 600 mg, 200 mgFilm-coated tablets.	51057951/20.2.8/0579Approved 17 February 2025	Registered	S4	PI PIL

Regulatory status

Where S4 sits on the scale

S0S1S2S3S4S5S6S7S8

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, matched to the Consolidated Schedules by ingredient, confidence medium.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Efavirenz, emtricitabine, tenofovir disoproxil fumarate

S4: Efavirenz
Consolidated Schedules 06 July 2026, line 6159
S4: Emtricitabine
Consolidated Schedules 06 July 2026, line 6178
S4: Tenofovir
Consolidated Schedules 06 July 2026, line 8130

Pharmacological class: Antiviral agents. (class 20.2.8)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

Odimune, Cipla Medpro Manufacturing (Pty) Ltd is scheduled S4 in its official SAHPRA documents, read with 90% confidence.

Professional information (PI)For healthcare professionalsOdimune, Cipla Medpro Manufacturing (Pty) Ltd Patient information leaflet (PIL)For patients and carersOdimune, Cipla Medpro Manufacturing (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background